Poolbeg Pharma Share Discussion Threads

[peterrr3] 29/8/2024 07:42

2 PR firms and a fund raising consultant liking and reposting the videos within minutes. Explaining what an orphan drug is, hardly aimed at pharma.

[peterrr3] 29/8/2024 07:17

Hi Pogue they are presenting at an investor conference run by the largest private placement firm in the US. Why on earth would they go there if it wasn't all about raising funds. They have finished doing the rounds with big pharma, nothing there. I think it is better to see what they are doing rather than what they said a few months ago.

[pogue] 29/8/2024 07:11

They have more than enough cash for 2 years and have said they do not need to raise funds. What is the premise for a fundraise? You are looking troll like with you unfounded nonsense. The fact they have one drug being sniffed around by 2 cancer companies looking to partner in a multi £billion market and an oral encapsulation method about to trial that has an instant and obvious market does not suggest a fund raise is necessary.

[peterrr3] 29/8/2024 06:54

Get prepared for plenty more froth. The dog and pony show got underway a couple of weeks ago, so expect some sort of Tik Tok sized video snip every few days from the CEO, Chief Business Officer and anyone else they can rope in. 4 so far. The focus of the fund raiser is obviously orphan drugs, POLB a bit of a side show now.

[lfdkmp] 27/8/2024 06:54

"Great to see @PoolbegPharma upcoming attendance and presentation..."

Is it?

Frankly I'm just about done with these frothy RNSs which detail little more than what should be normal business activity.

High time we were notified of substantive value added progress.

Whatever happened to the short runway, (whatever that meant)?

[burtond1] 27/8/2024 06:45

Great to see @PoolbegPharma upcoming attendance and presentation at the H.C. Wainwright 26th Annual Global Investment ConferenceJeremy Skillington and David Allmond will present virtually at the conference and the #POLB team will be available for in-person meetings with investors at the conference in New York on 9-11 September 2024.This conference offers an excellent opportunity to showcase their high value programmes for partnering their revenue focused business model and also plans to generate value for shareholders while addressing significant unmet medical needs across multiple disease areas.https://www.londonstockexchange.com/news-article/POLB/h-c-wainwright-global-investment-conference/16634765

[chica1] 21/8/2024 13:42

Had a little punt first thing this morning.
It's not for the faint at heart but NCYT's got pretty much the same market cap as POLB but has more cash,more revenue and and actual product to sell. (although not very wisely)
More than one can say about POLB..

[inaminute] 20/8/2024 14:25

As I was saying.......

[inaminute] 17/8/2024 11:11

NCYT is being pumped by the usual mob. Anyone buying in to it needs to know when they will dump. Do not be left holding the baby.

[chica1] 16/8/2024 16:01

Anyone nibble at Novacyt?
Looks like they may have an allay for MPOX..


David Allmond's old hunting ground.

[woodpeckers] 12/8/2024 13:06

Looks like he's trying to catch Cathal up ....

[inaminute] 12/8/2024 13:02

Holdings RNS out. Michael Kelly from 5.2% to 6.12%

[pogue] 03/8/2024 23:35

You don't have Baldrick on filter?

[anderson3] 03/8/2024 20:58

Baldrick, then sell up and move on?

[baldrick1] 03/8/2024 07:40

My weekend argument is polb current share price is way overvalued .. no revenues, not a hint of any large pharma eager to license polb1 and cash down to merely 12 million from the highs of 20 million.A Placings for new funding could be the next big news coming out..aimho

[chica1] 01/8/2024 17:20

I've always said I've held half on distribution from Hvivo.If POLB sign a deal with a pharma I'll be very happy but I'm willing to wait to see what that deal looks like.I'm willing to lose some upside if a potential deal happens.

Poolbeg is a very risky stock,do not gamble what you can't afford.
I've seem so many of these stocks crash and burn on the AIM..Avacta and Synairgen are 2 who have recently burned shareholders.

[inaminute] 01/8/2024 17:06

Usual halfwits turning up on here giving us the benefit of their lack of knowledge. When they are back in they will be pumping again. So transparent

[sikhthetech] 01/8/2024 14:31

Chica
"I said patents aren't worth didly squat unless the Actual Technology works."

Absolutely. Correct.

Even when companies have patents, where there's huge demand, other companies will try and find a way around and enter the market, as I proved with Byot. Ask 1gw and his mates how Byot crashed and became delisted due to the red flags I warned about.


With drugs there's a lifespan for patents. Generics appear all the time to compete with Brands.


sikhthetech - 24 Feb 2021 - 12:09:17 - 7693 of 12948 BYOTROL-CAN
supernumerary
"The need for cleansers and disinfectants really isn't going away:"


The point isn't whether there will be any demand but the huge demand during the initial stages of the pandemic won't be there as other other companies adapt and enter the market. Therefore, competition and supply increases.

[chica1] 01/8/2024 14:11

No you don't have clue adorling.What an idiotic statement.
I said patents aren't worth didly squat unless the Actual Technology works.
And we have no clue if POLB001 works.

There are 100's of millions of patents and trademarks that never see the light of day.
Companies apply for patents to protect their intellectual property but that doesn't mean that its actually any good.You can have a patent pending for years fyi.

[chica1] 01/8/2024 13:49

Patents aren't worth didly squat unless proprietary technology works.
There are millions of patents applied for annually and about 1% are actually used.

PepTcell/SeekGroup/ConserV/Imutex have numerous patents on their drug candidates going back 12 years yet none have gotten over the line.
Still hopefull for Hvivo's sake that ConserV/ Kimball Duncan can get FLU-V or the AGS-v (for malaria) to market.

[adorling] 01/8/2024 13:40

I see the lunatics have been let out of the asylum again. Looking forward to the next RNS landing soon :-)

[peterrr3] 01/8/2024 11:03

We will agree to disagree Pogue. They are trying to buy pipeline with the remaining cash. It has to be a technical evaluation. They use patent attorneys for the patents. They should have sacked them after the AI patent fiasco, or maybe that's the brief from the high powered management team they got lumbered with. Only got a fraction of the claims were accepted for the POLB second go patent referencing immunotherapy published last week. There is already an oral at clinical trial in the US 4 year timeline, you have to listen to what they actually say. Maybe that's where the lawyer comes in.

[klosters65] 01/8/2024 10:45

baldi - just stick to Blackadder.